15 December 2021: EsoBiotec is a biotechnology company developing an in vivo engineering platform to produce cancer fighting cells inside the patient’s body.
Walden: targeting podocytes as linchpin for kidney function
Walden, 29 October 2021: targeting podocytes as linchpin for kidney function.
Syndesi Therapeutics announces commencement of dosing in clinical trial of SDI-118 in elderly subjects with cognitive impairment
Syndesi, 21 October 2021: Syndesi Therapeutics announces commencement of dosing in clinical trial of SDI-118 in elderly subjects with cognitive impairment.
ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19
Belgium, 1 September 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of XVR011, its potent COVID-19 neutralizing antibody.
ExeVir announces first subjects dosed in Phase I clinical study of potent COVID-19 neutralizing antibody
Belgium, 18 August 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.
ExeVir’s CRO hunt for Phase II/III COVID-19 subQ antibody trial to start midyear, also USD 50– 100m Series B raise
13 Jul 2021. ExeVir Bio will open its doors to CRO pitches mid-year for a Phase II/III trial investigating its
subcutaneously administered neutralizing antibody XVR011 in outpatient COVID-19 patients, CEO
Torsten Mummenbrauer said. Decisions will be made in 2H21 for a 2Q22 trial start, he added.
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy
18 Jun 2021. Neurona is a cell therapy company focused on the development of breakthrough treatments for neurological disorders